At LIVVE, we know how much effort goes into looking after your health, and the last thing anyone wants is a rise in treatment costs. From September 2025, the manufacturer of Mounjaro (Eli Lilly) will be increasing the price of each dose by up to a maximum of 170% across the UK.
We want you to feel informed and supported, so here’s what this means and what your options are.
Why is the price going up?
When Mounjaro first launched in the UK in 2024, the price was set much lower than in other countries. This helped:
- The NHS get quicker access to supply.
- Keep private access affordable while global shortages were happening.
- Compete with Wegovy, which was licensed for obesity in late 2023.
Now, Eli Lilly is aligning UK prices with other countries like Germany, Australia, and the US. This means private patients here will start to see costs rise.
What about other weight-loss medicines?
Mounjaro isn’t the only option. Wegovy is still available at its current price and works in a very similar way:
- Once-weekly injection.
- Same style of pen and injection routine.
- Same need for healthy lifestyle changes alongside the medicine.
For many people, switching to Wegovy doesn’t feel like starting over it’s just a slightly different tool on the same journey. Your LIVVE clinician will look at your medical history, your goals, and how you’ve responded so far before advising if this is right for you.
What should you do if you’re affected?
If you’re paying privately for Mounjaro, it’s worth:
- Speaking to us at LIVVE: we can review your plan and talk through safe, affordable options.
- Reviewing your treatment goals: sometimes switching or adjusting your dose is the best step.
- Considering Wegovy or other approved treatments if appropriate.
Avoiding unlicensed sources: buying medicines online from unofficial sellers is unsafe and potentially dangerous.
Will this affect NHS prescriptions?
No. This increase only applies to the private list price.
If you’re eligible for tirzepatide through the NHS (for type 2 diabetes or obesity), the agreed NHS price will not change.
The LIVVE approach
We know news like this can feel unsettling, but you are not alone. At LIVVE, we’ll always be transparent with you and help you find the safest and most effective way forward. Whether that’s continuing on Mounjaro, considering Wegovy, or reviewing other options, our clinicians will support you at every step.
Your health journey doesn’t stop here and neither does our support.